Researchers one step closer to countering deadly Nipah virus

June 25, 2014, University of Texas Medical Branch at Galveston

An interdisciplinary research team from the University of Texas Medical Branch at Galveston, the Uniformed Services University of the Health Sciences and three groups within the National Institutes of Health reports a new breakthrough in countering the deadly Nipah virus. The human monoclonal antibody known as m102.4 is the first effective antiviral treatment for Nipah that has the potential for human therapeutic applications.

Nipah and the closely related Hendra are highly infectious agents that emerged from Pteropid fruit bats in the 1990s, causing serious disease outbreaks in a variety of domestic animals and humans in Australia, Malaysia, Singapore, Bangladesh and India. Recent Nipah outbreaks have resulted in acute respiratory distress syndrome and encephalitis, person-to-person transmission and greater than 90 percent fatality rates among people. These properties make both Nipah and Hendra viruses a concern to human and livestock health.

Previous studies conducted by these researchers have found that the patented m102.4 could protect from a deadly Hendra infection. In a paper appearing in Science Translational Medicine on June 25, the group describes the therapy that protected nonhuman primates from disease at several time points after Nipah exposure, including the onset of clinical illness in this lethal disease.

"What makes this study unique is that we have achieved complete protection against death even in animals that received treatment five days after being infected with the Nipah virus when they otherwise would have succumbed within 8-10 days of infection," according to UTMB professor Thomas Geisbert, first author of the paper. "This recent success of the antibody therapy against Nipah virus disease in a nonhuman primate is a key step towards its development as a therapeutic for use in people."

Christopher Broder, USU professor and Geisbert's fellow senior author, stated that because of the new data and previous work with this antibody with Hendra virus experiments, "there was sufficient interest for the Queensland government in Australia to initiate a phase I clinical safety trial with m102.4 that is set to commence later this year."

Explore further: Major advance in the treatment of Hendra virus reported

More information: "Therapeutic Treatment of Nipah Virus Infection in Nonhuman Primates with a Neutralizing Human Monoclonal Antibody," by T.W. Geisbert et al. stm.sciencemag.org/lookup/doi/ … scitranslmed.3008929

Related Stories

Major advance in the treatment of Hendra virus reported

October 19, 2011
A collaborative research team from Boston University School of Medicine (BUSM), the Uniformed Services University of the Health Sciences (USU), the University of Texas Medical Branch (UTMB) and Galveston National Laboratory ...

Test vaccine successfully protects monkeys from Nipah virus

August 8, 2012
Researchers have successfully tested in monkeys a vaccine against Nipah virus, a human pathogen that emerged in 1998 during a large outbreak of infection and disease among pigs and pig farmers in Southeast Asia. This latest ...

HJF works with global team to develop equine vaccine against deadly hendra virus

November 1, 2012
The technology used to develop a new vaccine as an aid in the prevention of clinical disease caused by Hendra virus in horses has been licensed from The Henry M. Jackson Foundation for the Advancement of Military Medicine, ...

Griffith University tackles deadly Hendra virus

June 4, 2012
Australian medical researchers are on the brink of an effective human treatment for the deadly Hendra virus, and potentially the closely related Nipah virus, which has killed more than two hundred people in South East Asia.

New bat virus could hold key to Hendra virus

August 2, 2012
Australian scientists have discovered a new virus in bats that could help shed light on how Hendra and Nipah viruses cause disease and death in animals and humans. The new virus - named 'Cedar' after the Queensland location ...

Biogeographic barrier that protects Australia from avian flu does not stop Nipah virus

April 24, 2013
An invisible barrier separates land animals in Australia from those in south-east Asia may also restrict the spillover of animal-borne diseases like avian flu, but researchers have found that fruit bats on either side of ...

Recommended for you

Flu may be spread just by breathing, new study shows; coughing and sneezing not required

January 18, 2018
It is easier to spread the influenza virus (flu) than previously thought, according to a new University of Maryland-led study released today. People commonly believe that they can catch the flu by exposure to droplets from ...

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Certain flu virus mutations may compensate for fitness costs of other mutations

January 18, 2018
Seasonal flu viruses continually undergo mutations that help them evade the human immune system, but some of these mutations can reduce a virus's potency. According to new research published in PLOS Pathogens, certain mutations ...

Zika virus damages placenta, which may explain malformed babies

January 18, 2018
Though the Zika virus is widely known for a recent outbreak that caused children to be born with microencephaly, or having a small head, and other malformations, scientists have struggled to explain how the virus affects ...

Study reveals how MRSA infection compromises lymphatic function

January 17, 2018
Infections of the skin or other soft tissues with the hard-to-treat MRSA (methicillin-resistant Staphylococcus aureus) bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. ...

Fresh approach to tuberculosis vaccine offers better protection

January 17, 2018
A unique platform that resulted in a promising HIV vaccine has also led to a new, highly effective vaccine against tuberculosis that is moving toward testing in humans.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.